گمعسس STIC-Biote	ech/ChemLib	182983	3/24 (3
From: Sent: To: Subject:	Thursday, N STIC-Bioted	David (AU1652) March 23, 2006 9:13 AM ch/ChemLib sequence alignment request	RECEI MR 23
NAME: Dav	id Steadman		EN STILL
AU:	1656		200 0) 2.00 0) 2.00
Date:	3/23/06		
Office:	Remsen 2B05		· ·
Mailbox:	Remsen 3C70		
		-	against SEQ ID NO:1 of application
Please sav	e results to diskette.		•
Thank you	very much.		nΑ
Primary Exam Art Unit 1656	allography and Recombina en 2B05	nt Enzymes	1-403 AA

Type of Search

\_\_\_\_Text:\_\_ \_\_Litigation:\_

NA#\_\_\_\_\_ AA#:\_\_ S/L:\_\_\_\_ Oligomer:\_ Encode/Transl:\_\_\_\_

Structure #:\_

Inventor:\_\_\_

Searcher:

Searcher Phone:

Date completed: \_\_\_\_\_ Searcher Prep Time:\_

Online Time:\_

Date Searcher Picked up: 2

QUESTEL/ORBIT: LEXIS/NEXIS: SEQUENCE SYSTEM:

WWW/Internet:\_ Other (Specify):\_

## **EAST Search History**

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	13528	(aik or aurora)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/03/23 10:35
S2	1245	S1 and crystal	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/03/23 09:30
<b>S3</b>	21	S1 near5 crystal	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/03/23 09:30
S4	190	(aik? adj protein) or (aurora\$ adj kinase) or (aur adj kinase) or (stk15 adj kinase) or (btak adj protein)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/03/23 10:42
S5	27	S4 and (crystal or (unit adj cell))	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/03/23 13:19
S6	190	(aik? adj protein) or (aurora\$ adj kinase) or (aur adj kinase) or (stk15 adj kinase) or (btak adj protein)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/03/23 13:20
S7	0	S6 and (cronin.in. or knuth.in. or mcree.in. or nowakowski.in. or pavletich.in. or thompson.in. or wijnands.in.)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/03/23 13:20
<b>S</b> 8	2	S6 and (takeda.as. or syrrx.as.)	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2006/03/23 13:21



## (19) World Intellectual Property Organization International Bureau



## 

#### (43) International Publication Date 17 April 2003 (17.04.2003)

#### **PCT**

# (10) International Publication Number WO 03/031606 A3

(51) International Patent Classification<sup>7</sup>:

C12N 9/12

- (21) International Application Number: PCT/GB02/04589
- (22) International Filing Date: 8 October 2002 (08.10.2002)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 0124299.9


10 October 2001 (10.10.2001) GE

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM, GR, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MK, MN, MW, MX, MZ, NL, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only): ASTRAZENECA AB [SE/SE]; Sodertalje, S-151 85 (SE).

- (71) Applicant (for MG only): ASTRAZENECA UK LIM-ITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1Y 6LN (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): ANDERSON, Malcolm [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). KEEN, Nicholas, John [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). PANNIFER, Andrew, David, Bruce [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). PAUPTIT, Richard, Alexander [NL/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB). ROWSELL, Sian [GB/GB]; Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
- (74) Agent: ASTRAZENECA; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,

[Continued on next page]

(54) Title: CRYSTAL STRUCTURE OF AN AURORA KINASE CATALYTIC DOMAIN, AND USE THEREOF



(57) Abstract: The invention provides crystalline forms of a polypeptide corresponding to the catalytic domain of Aurora kinase. The active site ATP binding pocket is defined by its amino acid residues and their atomic coordinates. This structure may be used to select or design chemical modulators of Aurora kinase, particularly Aurora inhibitors. These modulators may be used to treat diseases of cell proliferation, e.g. cancer.



WO 03/031606 A3

Interna Application No PCT/GB 02/04589

A CLASS	EICATION OF SUBJECT MATTER		- <del></del>
ÎPC 7	IFICATION OF SUBJECT MATTER C12N9/12		<del></del>
According to	o International Patent Classification (IPC) or to both national classific	cation and IPC	
	SEARCHED	<del></del>	
Minimum do IPC 7	ocumentation searched (classification system followed by classification ${\tt C12N}$	tion symbols)	
	tion searched other than minimum documentation to the extent that		
	ata base consulted during the International search (name of data ba		i)
BIOSIS	, EPO-Internal, WPI Data, PAJ, MEDL	INE	
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT		<del></del>
Category °	Citation of document, with indication, where appropriate, of the re	elevant passages	Relevant to claim No.
Υ	BISCHOFF JAMES R ET AL: "The Aug kinase family: Regulators of chro segregation and cytokinesis." TRENDS IN CELL BIOLOGY.	rora/Ipl1p omosome	1-11, 13-16
	vol. 9, no. 11, November 1999 (19) pages 454-459, XP002254572 ISSN: 0962-8924 the whole document	999-11),	
"Solutions for crystal growth"  HAMPTON RESEARCH, 'Online! 15 April 2001 (2001-04-15), XP002254573 Retrieved from the Internet: <url:http: 2001041520="" 5238="" hrproducts="" reens.html="" sc="" web="" web.archive.org="" www.hamptonresearch.com=""> 'retrieved on 2003-09-15! the whole document</url:http:>			
	-	-/	, 
X Furth	er documents are listed in the continuation of box C.	Patent family members are listed	in annex.
° Special cat	egories of cited documents :	NAME AND ADDRESS OF THE PARTY O	
CONSIGN	nt defining the general state of the art which is not ered to be of particular relevance ocument but published on or after the international	*T* later document published after the Inter or priority date and not in conflict with cited to understand the principle or the invention	the application but
"L" documer which is	ate ni which may throw doubts on priority claim(s) or s cited to establish the publication date of another	*X* document of particular relevance; the ci cannot be considered novel or cannot involve an inventive step when the doc	be considered to current is taken alone
citation "O" docume other m	or other special reason (as specified) nt referring to an oral disclosure, use, exhibition or neans	"Y" document of particular relevance; the cleant to connot be considered to involve an involve an involve an involve combined with one or more ments, such combination being obvious.	ventive step when the re other such docu-
tater that		in the art. "&" document member of the same patent f	•
	ctual completion of the International search	Date of mailing of the International seal	rch report
	September 2003  alling address of the ISA	30/09/2003 Authorized officer	:
	European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Hijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo ni,	Wimmer, G	
	Fax (+31-70) 340-3016	withiner, d	

Interna Application No
PCT/GB 02/04589

0.00	PCT/GB 02/04589		
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Callegory o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	
Y	MUELLER U ET AL: "Development of a technology for automation and miniaturization of protein crystallization" BRAUWELT, NUERNBERG, DE, vol. 85, no. 1, 23 January 2001 (2001-01-23), pages 7-14, XP004315104 ISSN: 0168-1656 the whole document	1-11, 13-16	
T	CHEETHAM GRAHAM M T ET AL: "Crystal structure of Aurora-2, an oncogenic serine/threonine kinase." JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 45, 8 November 2002 (2002-11-08), pages 42419-42422, XP002254574 ISSN: 0021-9258 the whole document	1-11, 13-16	
A	SARIDAKIS E ET AL: "IMPROVING PROTIEN CRYSTAL QUALITY BY DECOUPLING NUCLEATION AND GROWTH IN VAPOR DIFFUSION" PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 9, no. 4, April 2000 (2000-04), pages 755-757, XP009010758 ISSN: 0961-8368 the whole document	1-11, 13-16	

ial application No. PCT/GB 02/04589

Box I	Observations where certain claims were found unsearchable (Continuati	ion of item 1 of first sheet)
This int	nternational Search Report has not been established in respect of certain claims under Artic	cle 17(2)(a) for the following reasons:
1. 🛛	because they relate to subject matter not required to be searched by this Authority, nam	
	Claim 12 relates to a method of designing a three-disuch a threedimensional structure is merely a form of subject-matter of the claim is regarded to fall under 52(2)d.	of display of information,
2. X	Claims Nos.: because they relate to parts of the International Application that do not comply with the an extent that no meaningful International Search can be carried out, specifically:	prescribed requirements to such
	see FURTHER INFORMATION sheet PCT/ISA/210	
з	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second	and third sentences of Rule 6.4(a).
Box II	II Observations where unity of invention is lacking (Continuation of item 2	of first sheet)
This in	nternational Searching Authority found multiple inventions in this international application, a	as follows:
1. [	As all required additional search fees were timely paid by the applicant, this internation searchable claims.	al Search Report covers all
2	As all searchable claims could be searched without effort justifying an additional tee, the of any additional fee.	nie Authority did not invite payment
3.	As only some of the required additional search fees were timely paid by the applicant, to covers only those claims for which fees were paid, specifically claims Nos.:	this International Search Report
4.	No required additional search fees were timely paid by the applicant. Consequently, thi restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	is International Search Report is
Remar	ark on Protest	ccompanied by the applicant's protest.
	No protest accompanied the paym	nent of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 3 and 4 relate to a crystalline polypeptide defined by reference to certain parameters, wherein it is impossible to compare these parameters to what is set out in the prior art. Consequently, a lack of clarity arises to such an extent as to render a meaningful complete search impossible.

Likewise, claims 5 and 16 relate to a crystalline polypeptide defined by the presence of certain parameters, namely individual residues at specific steric coordinates. A comparison of such absolute individual steric coordinates with what is set out in the prior art appears not to be possible and/or meaningful, leading to a lack of clarity to such an extent as to render a complete search impossible.

Moreover, these claims therein relate to an extremely large number of possible compounds, however support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found only for the specific Aurora A kinase peptide crystals disclosed in the application.

Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to a crystalline form of an Aurora kinase.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



#### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization

International Bureau



## 

(43) International Publication Date 13 November 2003 (13.11.2003)

**PCT** 

## (10) International Publication Number WO 2003/092607 A3

(51) International Patent Classification<sup>7</sup>: C07D 401/14, 403/12, 417/12

A61K 31/517,

(21) International Application Number:

PCT/US2003/013605

(22) International Filing Date:

1 May 2003 (01.05.2003)

(25) Filing Language:

Engnsn

(26) Publication Language:

English

(30) Priority Data: 60/377,510

1 May 2002 (01.05.2002) US

(71) Applicant (for all designated States except US): VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US).

(72) Inventors; and

- (75) Inventors/Applicants (for US only): CHEETHAM, Graham [GB/GB]; 75 Hamble Drive, Abingdon OX14 3TF (GB). KNEGTEL, Ronald [NL/GB]; 92 Andersey Way, Abingdon OX14 5NW (GB). SWENSON, Lovorka [CA/US]; 5 Davis Road, Belmont, MA 02478 (US). COLL, Joyce, T. [US/US]; 7 Phillips Street, Westborough, MA 01581 (US). RENWICK, Suzanne [GB/GB]; 41 Loudwater Close, Sunbury on Thames, Middlesex TW16 6DD (GB). WEBER, Peter [DE/GB]; 76 West St. Helen Street, Abingdon OX14 5BP (GB).
- (74) Agents: HALEY, James, F. et al.; c/o Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### **Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

#### Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 5 February 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CRYSTAL STRUCTURE OF AURORA-2 PROTEIN AND BINDING POCKETS THEREOF

(57) Abstract: The present invention provides crystalline molecules or molecular complexes which comprise binding pockets of Aurora-2 or its homologues. The invention also provides crystals comprising Aurora-2. The present invention also relates to a computer comprising a data storage medium encoded with the structural coordinates of Aurora-2 binding pockets and methods of using a computer to evaluate the ability of a compound to bind to the molecule or molecular complex. This invention also provides methods of using the structure coordinates to solve the structure of homologous proteins or protein complexes. In addition, this invention provides methods of using the structure coordinates to screen for and design compounds, including inhibitory compounds, that bind to Aurora-2 or homologues thereof.



International application No.

PCT/US03/13605

IPC(7) US CL	IPC(7) : A61K 31/517; C07D 401/14, 403/12, 417/12				
	ng to International Patent Classification (IPC) or to both national classification and IPC				
	DS SEARCHED				
	cumentation searched (classification system followed 14/266.2, 266.21, 266.23; 544/284	by classification symbols)			
Documentation	on searched other than minimum documentation to th	e extent that such documents are included	in the fields searched		
	ata base consulted during the international search (nar pructure search	me of data base and, where practicable, so	earch terms used)		
C. DOC	UMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where a	opropriate, of the relevant passages	Relevant to claim No.		
A	WO 02/22602 A2 (VERTEX PHARMACEUTICAL (21.03.2002), whole document.	LS INCORPORATED) 21 March 2002	1-20, 32-34		
Further	documents are listed in the continuation of Box C.	See patent family annex.			
* S	pecial categories of cited documents:	"T" later document published after the inte			
	defining the general state of the art which is not considered to be lar relevance	date and not in conflict with the applic principle or theory underlying the inve	ntion .		
"B" earlier ap	plication or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider when the document is taken alone			
	which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as	"Y" document of particular relevance; the considered to involve an inventive step combined with one or more other such	when the document is		
"O" document	referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the			
	published prior to the international filing date but later than the ate claimed	"&" document member of the same patent i	amily		
•	ctual completion of the international search	Date of mailing of the international sear 28 NOV 2003	ch report		
	r 2003 (03.11.2003)	Abtivosidad officer			
Mai Cor P.C Ale	ailing address of the ISA/US il Stop PCT, Attn: ISA/US nmissioner for Patents . Box 1450 xandria, Virginia 22313-1450 b. (703)305-3230	Abellorized officer Richard L. Raymond  Telephone No. (703) 308-1235	ecto for		
Pacsimile INC	1. 1703 BUFBAN				

Form PCT/ISA/210 (second sheet) (July 1998)

International application No.

PCT/US03/13605

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)				
This interna	ional report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
i. 🗌	Claim Nos.: because they relate to subject matter not required to be searched by this Authority, namely:			
2.	Claim Nos.: because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:			
3. S 6.4(a)	Claim Nos.: 21-31 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule			
Box II O	bservations where unity of invention is lacking (Continuation of Item 2 of first sheet)			
This Interna	tional Searching Authority found multiple inventions in this international application, as follows:			
_				
1.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.			
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.			
3.	As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:			
••				
4.	No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:			
Remark on	Protest			
	No protest accompanied the payment of additional search fees.			

Form PCT/ISA/210 (continuation of first sheet(1)) (July 1998)

Stat





Contact Us | Help | Print Page

Home Search Structure Results
Queries

Clear queries

A MEMBER OF THE

# An Information Portal to Biological Macromol

As of Tuesday Mar 21, 2006 at there are 35701 Structures @

### **Query Manager**

All queries performed during the current web session are shown. (Click below to retrieve the results of a previous query)

- O XrayCellQuery: cell.length\_a.comparator=between cell.length\_a.mi cell.length\_a.max=84.48 cell.length\_b.comparator=between cell.length\_b.min=76.48 cell.length\_b.max=84.48 cell.length\_c.comparator=between cell.length\_c.min=163.57 cell.length\_c.max=180.79 cell.angle\_alpha.comparator=between cell.angle\_alpha.min= cell.angle\_alpha.max= cell.angle\_beta.comparator=between cell.angle\_beta.min= cell.angle\_beta.max= cell.angle\_gamma.comparator=between cell.angle\_gamma.min= cell.angle\_gamma.max=
- O Advanced Keyword Query for: aurora kinase

© RCSB Protein Da



## An Information Portal to Biologica

As of Tuesday Mar 21, 2006 there are 3570

PDB ID or keyword Author SEARCH) ( A

Structure Summary Biology & Chemistry Materials & Methods Sequence

Home Search Structure Results

Queries

10L7

Bi

... **=** 10L7

Download Files FASTA Sequence

Display Files

Display Molecule

**Structural Reports** 

Structure Analysis

STRUCTURE OF HUMAN AURORA-A Title 122-403 PHOSPHORYLATED ON

THR287, THR288

**Authors** Bayliss, R., Conti, E.

Bayliss, R., Sardon, T., Vernos, Primary I., Conti, E. Structural Basis of Aurora-A Activation by Tpx2 at the Mitotic Spindle Citation

Molecular Cell v12 pp.851, 2003

Deposition 2003-08-06 Release 2003-10-History

Experimental Type X-RAY DIFFRACTION Data Method

[EDS]

Resolution R-Value R-Free Space Group

[Å] ₩<u></u> **Parameters** 

0.257 P 6<sub>1</sub> 2 2 2.75 0.296 (obs.)

Unit Cell

Length a 81.18 b 81.18 c 169.62 [Å]

Angles alpha 90.00 beta 90.00 gamma 120.00

Molecular monomer (protein 282 residues)

Description Asymmetric Unit

Polymer: 1 Molecule: SERINE/THREONINE KINASE 6

Fragment: CATALYTIC DOMAIN, RESIDUES 122-403 Chains: A; EC No.:

Other Details:

PHOSPHORYLATED ON THR287,

**THR288** 

Functional Class

**Kinase** 


Source

Polymer: 1 Scientific Name: Homo sapiens (

system: Homo sapiens

Chemical

Component	Identifier	Formula					
	TPO	PHOSPHOTHREONINE			C <sub>4</sub> H <sub>10</sub> N O <sub>6</sub> P		
	MG	MAGNESIUI	M ION		Mg <sup>2+</sup>		
		ADENOSINE DIPHOSPHA			C <sub>10</sub> H <sub>15</sub>	N <sub>5</sub> O <sub>10</sub>	P <sub>2</sub>
SCOP Classification	Domain Info	Class	Fold		Superfa	mily	Fa
(version 1.69)	d1ol7a_	Alpha and beta proteins (a+b)	Protei kinase (PK-lil	-like	Protein kinase- (PK-lik	like	Pr kii ca su
CATH	Domain	Class		Archit	ecture	Торс	olog
Classification (version v2.6.0)	10l7A1	Mainly	Aipha	Ortho Bund	ogonal le	Tran (Pho dom	sp
•	1ol7A2	Alpha	Beta	2-Lay Sand		Phos Kina	
GO Terms	Polymer	1	Molecula			Biol	ogi
		THREONINE 6 (10L7:A)	• r	ctivity protein serine/	threonir activity	ie	•



## An Information Portal to Biologica

As of Tuesday Mar 21, 2006 there are 3570

PDB ID or keyword Author SEARCH

Structure Summary Biology & Chemistry Materials & Methods Sequence

1MQ4 🖺

Im

Bi

. A D.........

Title Crystal Structure of Aurora-A Protein Kinase

Nowakowski, J., Cronin, C.N., McRee, D.E., Knuth, M.W., Nelson, C., Pavletich, N.P., Rodgers, J., Sang, B.-C., Scheibe, D.N., Swanson,

R.V., Thompson, D.A.

**Authors** 

**Primary** 

Citation

Nowakowski, J., Cronin, C.N., McRee, D.E., Knuth, M.W., Nelson, C., Pavletich, N.P., Rodgers, J., Sang, B.-C., Scheibe, D.N., Swanson, R.V., Thompson, D.A. Structures of the Cancer-Related Aurora-A, FAK and EphA2

Protein Kinases from Nanovolume Crystallography Structure v10 pp.1659-1667, 2002

[Abstract] 🕲

History Deposition 2002-09-13 Release 2003-09-

Experimental
Method
Type X-RAY DIFFRACTION Data N/A

Resolution R-Value R-Free Space Group

1.90 0.227 (obs.) 0.273 P 6<sub>1</sub> 2 2

Unit Cell Length a 80.45 b 80.45 c 172.17 Angles [°] alpha 90.00 beta 90.00 gamma 120.00

Molecular monomer (protein 272 residues)
Description
Asymmetric Polymer: 1 Molecule: AURORA-

RELATED KINASE 1 Fragment: kinase domain Chains: A; EC No.: 2.7.-.-

Functional Class	Transf	erase		
Source	Polymer: system:	1 Scientific Name Homo sapiens	: Homo sapie	ns 🗨 (
Related PDB Entries	Id 1MQB 1MP8	KINASE	S THE CRYST/	
Chemical Component	MG	Name PHOSPHATE ION MAGNESIUM ION ADENOSINE-5'- DIPHOSPHATE	Mg <sup>2+</sup>	a , N <sub>5</sub> O <sub>10</sub> P <sub>2</sub>
SCOP Classification (version 1.69)	Domain Info d1mq4a_	Class Fold  Alpha and Proteins (PK-	se-like kinase	n Pr e-like kii
CATH Classification (version v2.6.0)	Domain 1mq4A1 1mq4A2	Class Mainly Alpha Alpha Beta	Architecture Orthogonal Bundle 2-Layer Sandwich	Topolog Transfe (Phosp domair Phosph Kinase;
GO Terms		A-RELATED • 1 (1MQ4:A)	protein kinase activity protein serine/threoni kinase activity serine/threoni kinase activity ATP binding	• ne



A MEMBER OF THE

# An Information Portal to Biological Macromol

As of Tuesday Mar 21, 2006 there are 35701 Structures @

Stat

Contact Us | Help | Print Page

Home Search Structure Results Queries PDB ID or keyword Author SEARCH. (Advanc

13 Structure Hits 66 Web Page Hits 0 Unreleased Structures

Results (1-10 of 13)

Refine this Search

Select All

37

**Deselect All** 

**Download Selected** 

Tabulate

Narrow Query

Sort Results

Results per Page

**Show Query Details** 

Results Help

12 🗘

☑ 2C6D

rd in se

**AURORA A KINASE ACTIVATED MU'** (T287D) IN COMPLEX WITH ADPNF

Release Date: 11-Jan-2006 Exp. Method:

Characteristics

Resolution: 2.20 Å

Classification

**Transferase** 

Compound

Mol. Id: 1 Molecule: Serine/threonine Prote Fragment: Catalytic Kinase Domain Residues

**Mutation: YES** 

**Authors** 

Heron, N.M., Anderson, M., Blower D.P., Breed, J., Eden, J.M., Green, G.B., Johnson, T., Jung, F.H., Mcm H.H.J., Mortlock, A.A., Pannifer, A. R.A., Pink, J., Roberts, N.J., Rowse

☑ 2C6E



AURORA A KINASE ACTIVATED MU (T287D) IN COMPLEX WITH A 5-ÀMINOPYRIMIDINYL QUINAZOLIN **INHIBITOR** 

Characteristics

Release Date: 11-Jan-2006 Exp. Method:

Resolution: 2.10 Å

Classification

Transferase/inhibitor Complex

Mol. Id: 1 Molecule: Serine/threonine Prote Fragment: Catalytic Kinase Domain Residues

**Mutation: YES** 

**Authors** 

Compound

Heron, N.M., Anderson, M., Blower D.P., Breed, J., Eden, J.M., Green, G.B., Johnson, T., Jung, F.H., Mcm

H.H.J., Mortlock, A.A., Pannifer, A. R.A., Pink, J., Roberts, N.J., Rowse

**回 10L7** 

rd in the

STRUCTURE OF HUMAN AURORA-A 403 PHOSPHORYLATED ON THR287 **THR288** 



Characteristics

Release Date: 30-Oct-2003 Exp. Method:

Resolution: 2.75 Å Kinase

Mol. Id: 1 Molecule: Serine/threonine Kina:


Fragment: Catalytic Domain Residues 122 40 Bayliss, R., Sardon, T., Vernos, I.,

Classification

Compound

Authors

STRUCTURE OF AURORA-A 122-403 ☑ 10L5 PHOSPHORYLATED ON THR287, TH **AND BOUND TO TPX2 1-43** Release Date: 30-Oct-2003 Exp. Method: Characteristics Resolution: 2.50 Å Classification Complex(kinase/cell Division Prote Mol. Id: 1 Molecule: Serine/threonine Kina: Fragment: Catalytic Domain Residues 122 40 Compound Molecule: Restricted Expression Proliferation. 100 Fragment: N Terminal Fragment Residu **Authors** Bayliss, R., Sardon, T., Vernos, I., ra i i i i STRUCTURE OF UNPHOSPHORYLAT **回 10L6 D274N MUTANT OF AURORA-A** Release Date: 30-Oct-2003 Exp. Method: Characteristics Resolution: 3.00 Å Classification Kinase Mol. Id: 1 Molecule: Serine/threonine Kina: Compound Fragment: Catalytic Domain Residues 122 40 **Mutation: YES** Authors Bayliss, R., Sardon, T., Vernos, I., **Crystal Structure of Aurora-A Prote** ☑ 1MQ4 Kinase Release Date: 16-Sep-2003 Exp. Method: Characteristics Resolution: 1.90 Å Classification **Transferase** Mol. Id: 1 Molecule: Aurora Related Kinase Compound Fragment: Kinase Domain Nowakowski, J., Cronin, C.N., McR. D.E., Knuth, M.W., Nelson, C., Pavl N.P., Rodgers, J., Sang, B.-C., Schi D.N., Swanson, R.V., Thompson, D Authors ra iii da CRYSTAL STRUCTURE OF AURORA-: ☑ 1MUO ONCOGENIC SERINE-THREONINE K Release Date: 15-Apr-2003 Exp. Method: Characteristics Resolution: 2.90 Å Classification Transferase Mol. Id: 1 Molecule: Aurora Related Kinase Compound Fragment: Aurora 2 Kinase Domain Residues Cheetham, G.M.T., Knegtel, R.M.A., J.T., Renwick, S.B., Swenson, L., V P., Lippke, J.A., Austen, D.A. Authors rd 🖹 🖾 Structure of the Kinase Domain of a ☑ 2F4J Imatinib-Resistant Abl Mutant in Co with the Aurora Kinase Inhibitor V)



12 ♥

© RCSB Protein Da



A MEMBER OF THE

# An Information Portal to Biological Macromol

As of Tuesday Mar 21, 2006 there are 35701 Structures @

Stat

Contact Us | Help | Print Page

Home Search Structure Results Oueries PDB ID or keyword Author ESEARCH: (Advanc

13 Structure Hits 66 Web Page Hits 0 Unreleased Structures

Results (11-13 of 13) Refine this Search

Select All

Deselect All

Download Selected

Tabulate

Narrow Query

Sort Results

Results per Page

**Show Query Details** 

Results Help

**(**) 12 ra in se

Characteristics

Classification

Compound

**COMPLEX OF AURORA-B WITH INC** AND HESPERIDIN.

Release Date: 03-May-2005 Exp. Method:

Resolution: 1.80 Å **Transferase Complex** 

Mol. Id: 1 Molecule: Loc398457 Protein Fragment: Catalytic Domain Residues 78 361

Mol. Id: 2 Molecule: XI Incenp Fragment

Fragment Residues 798 840

Sessa, F., Mapelli, M., Ciferri, C., T C., Areces, L.B., Schneider, T.R., S

P.T., Musacchio, A.

✓ 2BMC

☑ 2BFY

nig

**Authors** 

**AURORA-2 T287D T288D COMPLEX** WITH PHA-680632

Release Date: 17-Mar-2005 Exp. Method:

Characteristics

Resolution: 2.60 Å

Classification

**Transferase** 

Compound

Moi. Id: 1 Molecule: Serine Threonine Prote Fragment: Catalytic Domain Residues 100 40

**Mutation: YES** 

**Authors** 

Fancelli, D., Berta, D., Bindi, S., Ca A.D., Catana, C., Forte, B., Giordar P., Mantegani, S., Meroni, M., Moll V., Severino, D., Storici, P., Tonani M., Vulpetti, A., Vianello, P., Izzo, A., Rusconi, L.

☑ 1MQB

Crystal Structure of Ephrin A2 (eph **Receptor Protein Kinase** 

Characteristics

Release Date: 16-Sep-2003 Exp. Method:

Resolution: 2.30 Å Classification Transferase

Compound

Mol. Id: 1 Molecule: Ephrin Type a Recepto

Fragment: Kinase Domain

Authors

Nowakowski, J., Cronin, C.N., McR. D.E., Knuth, M.W., Nelson, C., Pavl N., Rogers, J., Sang, B.C., Scheibe,

D.N., Swanson, R.V., Thompson, D.A.

**\$12** 

© RCSB Protein Da





(11) **EP 1 522 580 A1** 

(12)

#### **EUROPEAN PATENT APPLICATION**

(43) Date of publication: 13.04.2005 Bulletin 2005/15

(51) Int CI.7: **C12N 9/12**, C07K 14/47, C07D 209/42

(21) Application number: 03023136.9

(22) Date of filing: 10.10.2003

(84) Designated Contracting States:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IT LI LU MC NL PT RO SE SI SK TR

Designated Extension States:

AL LT LV MK

(71) Applicant: EMBL D-69117 Heidelberg (DE)

(72) Inventors:

Conti, Elena
 69126 Heidelberg (DE)

 Bayliss, Richard London NW4 1DJ (GB)

 Schultz, Carsten 69117 Heldelberg (DE) Vernos, Isabelle
 69115 Heidelberg (DE)

Sardon, Teresa
 69115 Heidelberg (DE)

(74) Representative: Wolter, Thomas, Dr. et al Reitstötter, Kinzebach & Partner (GbR) Patentanwälte Sternwartstrasse 4 81679 München (DE)

#### Remarks:

The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

- (54) Crystals of an aurora-a tpx2 complex, tpx2 binding site of aurora-a, aurora-a ligands and their use
- (57) The present invention relates to crystals of phosphorylated Aurora-A kinase fragment alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands, in particular allosteric inhibitors of Aurora-A, that bind to the Aurora-A kinase and their use. Further, the present invention relates to certain indene and indole derivatives. The present in-

vention relates to crystals of phosphorylated Aurora-A kinase alone and in complex with a ligand, amino acid residues 1-43 of human TPX2. This invention also relates to methods for designing and selecting ligands that bind to the Aurora-A kinase and their use. Further, the present invention relates to certain indene and indole derivatives.

EP 1 522 580 A1



## PARTIAL EUROPEAN SEARCH REPORT

**Application Number** 

which under Rule 45 of the European Patent Convention EP 03 02 3136 shall be considered, for the purposes of subsequent proceedings, as the European search report

	DOCUMENTS CONSID	ERED TO BE RELEVANT	,	
Category	Citation of document with i of relevant pass	ndication, where appropriate, ages	Refevant to claim	CLASSIFICATION OF THE APPLICATION (Int.CI.7)
Х	WO 03/031606 A (PAI BRUCE ;PAUPTIT RICH ROWSE) 17 April 200 * the whole documen	NNIFER ANDREW DAVID HARD ALEXANDER (GB); 93 (2003-04-17) nt *	5,9	C12N9/12 C07K14/47 C07D209/42
D,X	for activation of f Aurora A." CURRENT BIOLOGY, vol. 13, no. 8,	3-04-15), pages 691-697,	5	
γ	* the whole documer	1t *	1-4	
x	the spindle" JOURNAL OF CELL BIO vol. 158, no. 4,	ing Aurora-A kinase to DLOGY,	5	
	19 August 2002 (200 617-623, XP00227501	2-08-19), pages 3		TECHNICAL FIELDS SEARCHED (Int.CI.7)
Y	ISSN: 0021-9525 * the whole documer	t *	1-4	C12N   C07K   C07D
		-/		
The Searce not comply be carried Chairns search	h Division considers that the present	application, or one or more of its claims, does/o a meaningful search into the state of the art car by, for these claims.	do .	inama ta et kiril kirilini, inamana
	r the limitation of the search:			
	Piaco of soarch Munich	Date of completion of the search 25 March 2004	Sch	Examiner wachtgen, J-L
CA X : partic Y : partic	TEGORY OF CITED DOCUMENTS cularly relevant if taken alone cularly relevant if combined with another ment of the same category	T: theory or principle E: earlier patent docu after the filing date	underlying the is ment, but publis the application	nvention



### PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 03 02 3136

	OCUMENTS CONSIDERED TO BE RELEVANT		CLASSIFICATION OF THE APPLICATION (Int.CI.7)	
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim		
Y	MUELLER U ET AL: "Development of a technology for automation and miniaturization of protein crystallization" BRAUWELT, NUERNBERG, DE, vol. 85, no. 1, 23 January 2001 (2001-01-23), pages 7-14, XP004315104 ISSN: 0168-1656 * the whole document *	1-4		
	BAYLISS RICHARD ET AL: "Structural basis of Aurora-A activation by TPX2 at the mitotic spindle." MOLECULAR CELL, vol. 12, no. 4, October 2003 (2003-10), pages 851-862, XP002275014 ISSN: 1097-2765 (ISSN print)		TECHNICAL FIELDS SEARCHED (Int.CL7)	
j	WO 94/03427 A (WARNER LAMBERT CO) 17 February 1994 (1994-02-17) * the whole document *			
·	**************************************			
	·			
	<u>.</u>			



#### INCOMPLETE SEARCH SHEET C

Application Number EP 03 02 3136

Claim(s) not searched: 6-8

Reason for the limitation of the search (non-patentable invention(s)):

Article 52 (2)(d) EPC - Presentation of information

Further limitation of the search

Claim(s) not searched: 10-12, 24-26

Reason for the limitation of the search:

Claims 10-12 and 24 (in part) relate to compounds defined as modulators or allosteric inhibitors, which bind to any of a number of residues of Aurora-A. The claims cover all such compounds, whereas the application provides support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC no such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search is impossible. Independent of the above reasoning, the claims also lack clarity (Article 84 EPC) as an attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search impossible.

The same objection applies to claims 25 and 26, insofar as they relate to uses of the compounds according to claims 10-12.



Application Number

EP 03 02 3136

CLAIMS INCURRING FEES
The present European patent application comprised at the time of filing more than ten claims.
Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.
LACK OF UNITY OF INVENTION
The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:
see sheet B
All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:  1-5, 9



# LACK OF UNITY OF INVENTION SHEET B

Application Number EP 03 02 3136

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-5, 9

A crystal of phosphorylated Aurora-A kinase complexed with human  $\ensuremath{\mathsf{TPX2}}$ 

2. claims: 13-26

Indole and indene derivatives and their uses

····

#### ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 03 02 3136

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

25-03-2004

	ent document in search report		Publication date		Patent family member(s)	Publication date
WO 0	3031606	Α	17-04-2003	WO	03031606 A2	17-04-2003
WO 9	403427	A	17-02-1994	AU AU CA CZ EP HU JP RU SK WO US	672224 B2 4799493 A 2140440 A1 9500288 A3 0654024 A1 71553 A2 8503450 T 2155187 C2 13595 A3 9403427 A1 5464861 A 5556874 A	26-09-1996 03-03-1994 17-02-1994 12-06-1996 24-05-1995 28-12-1995 16-04-1996 27-08-2000 13-09-1995 17-02-1994 07-11-1995 17-09-1996
				US	55568/4 A	17-09-1996
-			·			·
	•					

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82





#### A service of the National Library of Medicine and the National Institutes of Health

My NCBI 2 [Sign In] [Register]

All Databases	PubMed	Nucleotide	Protein	Genome	Structure	ОМІМ	PMC	Journals	Books
Search MeSH		for					Go	Clear	
	Limit	s Preview/Ind	lex History	Clipboard	d V Details	`			
About Entrez NCBI Toolbar	Display	<u> </u>			She	ow 20	Send	to	Į.
Text Version	All: 1	<u> </u>							

Entrez PubMed Overview Help | FAQ Tutorials New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries Special Queries LinkOut My NCBI

Related Resources Order Documents **NLM Mobile** NLM Catalog **NLM Gateway** TOXNET Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

- If making selections (e.g., Subheadings, etc.), use the Send to Search Box feature to see PubMed recor with those specifications.
- Select PubMed under the Links menu to retrieve all records for the MeSH Term.
- Select NLM MeSH Browser under the Links menu for additional information.

#### 1: aurora kinase [Substance Name]

Lir

highly conserved in eukaryotes and involved in many processes during cell division; Aurora A regulate centrosome function during M phase; Aurora-B plays roles in spindle dynamics, chromosome condensation, and cytokinesis Date introduced: May 18, 1995

Registry Number: EC 2.7.1.-

Heading Mapped to:

Protein-Serine-Threonine Kinases

#### Entry Terms:

- aur kinase
- aurora kinase A
- Aik protein
- AURORA2 protein
- Breast-tumor-amplified kinase
- BTAK protein
- serine/threonine protein kinase 15
- STK15 kinase
- aurora kinase B
- AIK2 protein
- aurora-related kinase 2
- auroral protein
- serine/threonine protein kinase 12
- STK12 protein aurora kinase C
- AIK3 protein
- Aurora/Ipl1-related kinase 3
- Serine/threonine-protein kinase 13
- STK13 protein

CII	 1/2			One of An	100
Display   Full	Show	120	<b>Y</b> 4	Sena to	li N
Display J	 Silow		ر است		1640

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer

Mar 13 2006 06:33:20







A service of the National Library of Medicine and the National Institutes of Health

My NCBI [Sign In] [Re

			•						
All Databases	PubMed	Nucleotide	Protein	Genome	Structure	OMIM	PMC	Journals	
Search PubMed		for [					Pre	view Go	
	Limits	Y Preview	/Index I	Nistory	Clipboard	✓ Details	5		
Alegant Contract	• Searc	h History	will be lo		eight hours		-	A. T. 116	

About Entrez NCBI Toolbar

**Text Version** 

• To combine searches use # before search number, e.g., #2 AND #6. • Search numbers may not be continuous; all searches are represented.

• Click on query # to add to strategy

Entrez PubMed
Overview
Help   FAQ
Tutorials
New/Noteworthy
E-Utilities

**PubMed Services** Journals Database MeSH Database Single Citation Matcher **Batch Citation** Matcher Clinical Queries **Special Queries** LinkOut

My NCBI

Search **Most Recent Queries** Time Result #6 Related Articles for PubMed (Select 09:22:06 101 12467573) #5 Related Articles for PubMed (Select 09:21:52 106 12237287) #4 Search #3 AND (crystal OR crystallization) 09:21:34 #3 Search "aurora kinase" [Substance Name] 09:20:48 234

Clear History

Related Resources **Order Documents NLM Mobile NLM Catalog NLM Gateway TOXNET** Consumer Health Clinical Alerts ClinicalTrials.gov PubMed Central

> Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Privacy Statement | Freedom of Information Act | Disclaimer

> > Mar 13 2006





Return to the USPTO NPL Page | Help

🖅 My Research Advanced Publications % Basic 0 marked items

Interface language: English .▼.

<u>Databases selected:</u> ProQuest Dissertations and Theses - Full Text

## My Research

Back to Results

• Create a web page with links to your articles, searches, and publications.

#### Marked Documents

Recent Searches | Visited Publications

Marked Documents lets you save documents you find useful. To add documents to your marked items:

- With Results displayed--Select the check box to the left of a document title.
- With a document displayed--Select the "mark document" check box on the document display page.

Once you have documents marked, you can create your bibliography, email marked documents, export citations, or create a web page with links to your articles.

#### **Recent Searches**

Marked Documents | Visited Publications

4 results as of March 23, 2006

1. (aurora or aik or ipl1p) and Set Up Alert⊠

crystal

Database: ProQuest

Dissertations and Theses - Full

Text

Look for terms in: Citation and

abstract

Publication type: All publication

types

2. aurora-a OR aurora-2

Set Up Alert⊠

16 results as of March 23. 2006

Database: ProQuest Dissertations and Theses - Full

Text

Look for terms in: Citation and

abstract

Publication type: All publication

types

Visited Publications

Marked Documents | Recent Searches

<sup>\*</sup> The maximum number of documents you can save is 50.